Published in Int J Radiat Oncol Biol Phys on February 01, 2005
PET: too much of a good thing? Does the plethora of choices impact on patient management? Eur J Nucl Med Mol Imaging (2005) 0.75
Staging of advanced cervical cancer. Int J Radiat Oncol Biol Phys (2005) 0.75
Survival outcomes in patients with cervical cancer after inclusion of PET/CT in staging procedures. Eur J Nucl Med Mol Imaging (2015) 0.75
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol (2004) 4.69
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 4.13
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med (2006) 3.20
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med (2006) 3.15
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol (2008) 2.96
Staging of neuroblastoma at imaging: report of the radiology diagnostic oncology group. Radiology (2002) 2.87
Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med (2009) 2.84
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74
Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg (2004) 2.65
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. J Nucl Med (2015) 2.47
Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol (2007) 2.32
The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer (2007) 2.30
Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol (2005) 2.26
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging (2003) 2.25
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA (2007) 2.22
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol (2011) 2.19
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer (2009) 2.15
The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review. J Nucl Med (2013) 2.14
Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys (2003) 2.09
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Positron emission tomography with [(18)F]-3'-deoxy-3'fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol (2013) 2.05
Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol (2014) 2.05
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys (2009) 2.05
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol (2013) 2.01
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol (2010) 1.98
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol (2007) 1.87
Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol (2011) 1.86
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A (2003) 1.83
Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol (2002) 1.83
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.82
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer (2014) 1.80
Helical tomotherapy planning for left-sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique. Int J Radiat Oncol Biol Phys (2009) 1.79
Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol (2009) 1.75
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys (2004) 1.70
Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med (2014) 1.68
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol (2011) 1.67
Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol (2011) 1.66
Retrorectal tumors: a diagnostic and therapeutic challenge. Dis Colon Rectum (2005) 1.65
Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care (2002) 1.65
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med (2008) 1.62
11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med (2013) 1.60
Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol (2009) 1.59
Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol (2012) 1.58
Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol (2002) 1.57
Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res (2011) 1.57
Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J Surg (2010) 1.57
Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol (2004) 1.57
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet (2004) 1.57
Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. Obstet Gynecol (2010) 1.56
The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. Obstet Gynecol (2010) 1.56
Scientific evidence underlying the American College of Obstetricians and Gynecologists' practice bulletins. Obstet Gynecol (2011) 1.55
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol (2010) 1.55
Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010. Obstet Gynecol (2012) 1.55
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol (2013) 1.54
A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52